United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for NovaBay Pharmaceuticals, Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -453.56% | - | -925.39% | - | - | - |
|---|---|---|---|---|---|---|
| ROA | -115.97% | -55.75% | -46.27% | -57.78% | -61.83% | -60.73% |
| Gross Margin | 66.26% | 64.14% | 63.37% | 62.92% | 62% | 62.09% |
| Net Margin | -73.85% | -17.58% | -14.4% | -17.21% | -18.37% | -17.95% |
| Total Assets | $3,423.00K | $3,662.44K | $3,921.04K | $4,200.32K | $4,501.94K | $4,827.70K |
| Net Income | -$7,223.00K | -$1,975.21K | -$1,754.43K | -$2,346.20K | -$2,690.50K | -$2,832.83K |